bluuebunny/crossref_metadata_2025_split huggingface dataset:
College and Professional Women’s Basketball Players’ Lower Extremity Injuries: A Survey of Career Incidence
Authors: Gordon Abby I. , DiStefano Lindsay J. , Denegar Craig R. , Ragle Rosemary B. , Norman Jeremy R. 
Published: August 2014

Context:Lower extremity injuries in women’s basketball players are generally presented as seasonal team incidence. Available data were reported by team athletic trainers to overseeing bodies yielding estimates of injury rates as a percentage of all injuries sustained. By summarizing career incidence of women’s basketball players’ injuries, a new perspective indicating potential risk of injury can be considered.Objectives:To summarize the career incidence of lower extremity injuries in intercollegiate and professional women’s basketball players, examine the effect of anterior cruciate ligament (ACL) injury on professional basketball players’ career longevity, and explore the relationship between ankle sprains and knee injuries in this population.Design:Survey.Participants:246 elite-level women’s basketball players.Outcome Measures:Career incidence of lower extremity injury, professional career length, relationship between history of ankle sprain and ACL injury frequency calculations, and chi-square statistics. Results: Seventy-four of 85 (87.06%) professional Women’s National Basketball Association (WNBA) and 172/179 (96.09%) available collegiate Big East Conference (BEC) women’s basketball players completed the survey. Ankle sprains were the most frequently reported injury with 170/246 (69.11%) participants indicating at least one during their career. Patellar tendinopathy (28.46%), meniscal injury (22.76%), and ACL tear (21.54%) were also common. Professional career length in participants with an ACL reconstruction averaged 6.11 ± 3.20 seasons, more than the 5.70 ± 4.17 seasons reported by those without an ACL injury. Professional participants who did not report an ankle sprain were more likely to report an ACL tear (χ2 = 10.96; p = .000932).Conclusion:Summarizing career incidence provides a new perspective of women’s basketball players’ injuries. Ankle sprains and knee injuries were commonly reported, both more frequently than by traditional research methods. These data may assist in developing injury prevention and rehabilitation strategies for injured athletes.
Prospective Associations Between Physical Activity Level and Body Composition in Adolescence: 1993 Pelotas (Brazil) Birth Cohort
Authors: Reichert Felipe Fossati , Wells Jonathan Charles Kingdom , Ekelund Ulf , Menezes Ana Maria Baptista , Victora Cesar Gomes , Hallal Pedro C. 
Published: August 2014

Background:Physical activity may influence both fat and lean body mass. This study investigated the association between physical activity in children between the ages of 11 and 13 years and both fat and lean mass.Methods:A subsample of the 1993 Pelotas (Brazil) Birth Cohort was visited in 2004–2005 and 2006–2007. Physical activity was estimated through standardized questionnaires. Body composition (ie, fat and lean mass) was measured using deuterium dilution. Those with moderate-to-vigorous activity greater than 420 min/wk were classified as active, and physical activity trajectory was defined as being above or below the cutoff at each visit.Results:Four hundred eighty-eight adolescents (51.8% boys) were evaluated. The mean difference in fat mass in boys and girls who reported ≥ 420 min/wk of physical activity in both visits compared with those who were consistently inactive was –4.8 kg (P ≤ .001). There was an inverse association between physical activity and fat mass among boys in both crude and confounder-adjusted analyses, whereas for girls, the association was evident only in the crude analysis. There was no significant association between physical activity and lean mass.Conclusion:Physical activity may contribute to tackling the growing epidemic of adolescent obesity in low- and middle-income countries.
Characteristics of Walking Group Leaders as Compared with Walking Group Members in a Community-Based Study
Authors: Wilcox Sara , Forthofer Melinda , Sharpe Patricia A. , Hutto Brent 
Published: August 2014

Background:Walking interventions delivered by lay leaders have been shown to be effective. Knowing the characteristics of individuals who volunteer to be group leaders in walking programs could facilitate more efficient and effective recruitment and training.Methods:Walking group leaders were recruited into a community-based program and formed walking groups from existing social networks. Leaders and members completed a survey, participated in physical measurements, and wore an accelerometer. Regression models (adjusting for group clustering and covariates) tested psychosocial and behavioral differences between leaders and members.Results:The sample included 296 adults (86% women, 66% African American). Leaders (n = 60) were similar to members (n = 236) with respect to most sociodemographic and health characteristics, but were significantly older and more likely to report arthritis and high cholesterol (P-values < .05). Although leaders and members were similar in sedentary behavior and physical activity, leaders reported higher levels of exercise self-regulation, self-efficacy, and social support (P-values < .01). Leaders also reported greater use of outdoor trails (P = .005) and other outdoor recreation areas (P = .003) for physical activity than members.Conclusion:Although walking group leaders were no more active than members, leaders did display psychosocial characteristics and behaviors consistent with a greater readiness for change.
Genome Sequence of Rhodococcus opacus Strain R7, a Biodegrader of Mono- and Polycyclic Aromatic Hydrocarbons
Authors: Di Gennaro P. , Zampolli J. , Presti I. , Cappelletti M. , D'Ursi P. , Orro A. , Mezzelani A. , Milanesi L. 
Published: August 2014

ABSTRACT

Rhodococcus opacus
strain R7 (CIP107348) degrades several mono- and polycyclic aromatic hydrocarbons. Here, we present the high-quality draft genome sequence of strain R7, consisting of 10,118,052 bp, with a G+C content of 67.0%, 9,602 protein-coding genes, and 62 RNAs genes.
Availability and quality of mobile health app privacy policies
Authors: Sunyaev Ali , Dehling Tobias , Taylor Patrick L , Mandl Kenneth D 
Published: August 2014

Abstract
Mobile health (mHealth) customers shopping for applications (apps) should be aware of app privacy practices so they can make informed decisions about purchase and use. We sought to assess the availability, scope, and transparency of mHealth app privacy policies on iOS and Android. Over 35 000 mHealth apps are available for iOS and Android. Of the 600 most commonly used apps, only 183 (30.5%) had privacy policies. Average policy length was 1755 (SD 1301) words with a reading grade level of 16 (SD 2.9). Two thirds (66.1%) of privacy policies did not specifically address the app itself. Our findings show that currently mHealth developers often fail to provide app privacy policies. The privacy policies that are available do not make information privacy practices transparent to users, require college-level literacy, and are often not focused on the app itself. Further research is warranted to address why privacy policies are often absent, opaque, or irrelevant, and to find a remedy.
Long-term mortality after community-acquired pneumonia—impacts of diabetes and newly discovered hyperglycaemia: a prospective, observational cohort study
Authors: Koskela Heikki O , Salonen Päivi H , Romppanen Jarkko , Niskanen Leo 
Published: August 2014

ObjectivesCommunity-acquired pneumonia is associated with a significant long-term mortality after initial recovery. It has been acknowledged that additional research is urgently needed to examine the contributors to this long-term mortality. The objective of the present study was to assess whether diabetes or newly discovered hyperglycaemia during pneumonia affects long-term mortality.DesignA prospective, observational cohort study.SettingA single secondary centre in eastern Finland.Participants153 consecutive hospitalised patients who survived at least 30 days after mild-to-moderate community-acquired pneumonia.InterventionsPlasma glucose levels were recorded seven times during the first day on the ward. Several possible confounders were also recorded. The surveillance status and causes of death were recorded after median of 5 years and 11 months.ResultsIn multivariate Cox regression analysis, a previous diagnosis of diabetes among the whole population (adjusted HR 2.84 (1.35–5.99)) and new postprandial hyperglycaemia among the non-diabetic population (adjusted HR 2.56 (1.04–6.32)) showed independent associations with late mortality. New fasting hyperglycaemia was not an independent predictor. The mortality rates at the end of follow-up were 54%, 37% and 10% among patients with diabetes, patients without diabetes with new postprandial hyperglycaemia and patients without diabetes without postprandial hyperglycaemia, respectively (p<0.001). The underlying causes of death roughly mirrored those in the Finnish general population with a slight excess in mortality due to chronic respiratory diseases. Pneumonia was the immediate cause of death in just 8% of all late deaths.ConclusionsA previous diagnosis of diabetes and newly discovered postprandial hyperglycaemia increase the risk of death for several years after community-acquired pneumonia. As the knowledge about patient subgroups with an increased late mortality risk is gradually gathering, more studies are needed to evaluate the possible postpneumonia interventions to reduce late mortality.
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients
Authors: Navarese Eliano Pio , Kowalewski Mariusz , Kandzari David , Lansky Alexandra , Górny Bartosz , Kołtowski Łukasz , Waksman Ron , Berti Sergio , Musumeci Giuseppe , Limbruno Ugo , van der Schaaf Rene J , Kelm Malte , Kubica Jacek , Suryapranata Harry 
Published: August 2014

BackgroundFirst-generation drug-eluting stents (DES) have become the most widely used devices worldwide for management of coronary artery disease. As remote follow-up data were becoming available, concerns emerged in regard to their long-term safety. Second-generation DES were designed to overcome safety issues, but the results of randomised clinical trials remain conflicting.MethodsWe compared the safety and efficacy of first-generation versus second-generation Food and Drug Administration approved DES; the following devices were included: first-generation sirolimus-eluting stent (SES) and paclitaxel-eluting stents (PES); second-generation everolimus-eluting stent (EES), zotarolimus-eluting stent Endeavor and ZES-Resolute (ZES-R). Prespecified safety end points comprised ≤1 and >1 year: overall and cardiac mortality, myocardial infarction (MI), definite/definite or probable ST; efficacy end points were target lesion revascularisation and target vessel revascularisation. Composite end points were analysed as well.Results33 randomised controlled trials involving 31 379 patients with stable coronary artery disease or acute coronary syndrome undergoing DES implantation were retrieved. No differences in mortality among devices were found. In the overall class comparison, second-generation DES were associated with a 22% reduction of odds of MI at short-term OR 0.77 (95% CI 0.68 to 0.89) p=0.0002; EES reduced the odds of definite-probable ST compared with PES: OR 0.33 (95% CI 0.15 to 0.73) p=0.006; First-generation SES along with second-generation EES and ZES-R showed similar efficacy in decreasing the odds of repeat revascularisation.ConclusionsSecond-generation EES and ZES-R offer similar levels of efficacy compared with first-generation SES, but are more effective than PES; however, only second-generation EES significantly reduced the incidence of MI and ST, and therefore should be perceived as the safest DES to date.
Synergy between the NAMPT Inhibitor GMX1777(8) and Pemetrexed in Non–Small Cell Lung Cancer Cells Is Mediated by PARP Activation and Enhanced NAD Consumption
Authors: Chan Manuel , Gravel Michel , Bramoullé Alexandre , Bridon Gaëlle , Avizonis Daina , Shore Gordon C. , Roulston Anne 
Published: August 2014

Abstract
GMX1778 and its prodrug GMX1777 represent a new class of cancer drugs that targets nicotinamide phosphoribosyltransferase (NAMPT) as a new strategy to interfere with biosynthesis of the key enzymatic cofactor NAD, which is critical for a number of cell functions, including DNA repair. Using a genome-wide synthetic lethal siRNA screen, we identified the folate pathway–related genes, deoxyuridine triphosphatase and dihydrofolate reductase, the silencing of which sensitized non–small cell lung carcinoma (NSCLC) cells to the cytotoxic effects of GMX. Pemetrexed is an inhibitor of dihydrofolate reductase currently used to treat patients with nonsquamous NSCLC. We found that combining pemetrexed with GMX1777 produced a synergistic therapeutic benefit in A549 and H1299 NSCLC cells in vitro and in a mouse A549 xenograft model of lung cancer. Pemetrexed is known to activate PARPs, thereby accelerating NAD consumption. Genetic or pharmacologic blockade of PARP activity inhibited this effect, impairing cell death by pemetrexed either alone or in combination with GMX1777. Conversely, inhibiting the base excision repair pathway accentuated NAD decline in response to GMX and the cytotoxicity of both agents either alone or in combination. These findings provide a mechanistic rationale for combining GMX1777 with pemetrexed as an effective new therapeutic strategy to treat nonsquamous NSCLC. Cancer Res; 74(21); 5948–54. ©2014 AACR.
C-reactive Protein and Risk of Colorectal Adenomas or Serrated Polyps: A Prospective Study
Authors: Crockett Seth D. , Mott Leila A. , Barry Elizabeth L. , Figueiredo Jane C. , Burke Carol A. , Baxter Gwen J. , Sandler Robert S. , Baron John A. 
Published: August 2014

Abstract
Serum C-reactive protein (CRP) is a sensitive marker of systemic inflammation. Because there is a well-recognized relationship between local inflammation and colorectal cancer, we aimed to evaluate whether serum CRP levels were associated with the occurrence of colorectal adenomas and serrated polyps using data from a large adenoma prevention trial. A total of 930 participants with a history of colorectal adenomas were enrolled in a randomized trial of calcium supplementation (1,200 mg/day) for the prevention of colorectal adenomas. Outcomes in this analysis are metachronous adenomas (and advanced neoplasms specifically), and serrated polyps at follow-up colonoscopy. High-sensitivity CRP levels were measured 1 year following baseline colonoscopy. Multivariate analysis was performed to estimate risk ratios (RR) using Poisson regression, controlling for potential confounders. We measured serum CRP levels in 689 participants (mean CRP, 3.62 ± 5.72 mg/L). There was no difference in CRP levels with respect to calcium versus placebo treatment assignment (P = 0.99). After adjustment for potential confounders, we found no association between CRP level and risk of recurrent adenoma or advanced lesion [quartile 4 vs. quartile 1: RR, 95% confidence interval (CI) = 0.99 (0.73–1.34) and 0.92 (0.49–1.75), respectively]. Similarly, no association was seen between CRP levels and risk of serrated polyps or proximal serrated polyps [quartile 4 vs. quartile 1: RR (95% CI) = 1.32 (0.85–2.03) and 1.19 (0.54–2.58), respectively]. In conclusion, this large prospective colorectal adenoma chemoprevention study found no significant relationship between CRP levels and occurrence of adenomas, advanced neoplasms, or serrated polyps. Cancer Prev Res; 7(11); 1122–7. ©2014 AACR.
Plasma Membrane Calcium ATPase Isoform 4 Inhibits Vascular Endothelial Growth Factor–Mediated Angiogenesis Through Interaction With Calcineurin
Authors: Baggott Rhiannon R. , Alfranca Arantzazu , López-Maderuelo Dolores , Mohamed Tamer M.A. , Escolano Amelia , Oller Jorge , Ornes Beatriz C. , Kurusamy Sathishkumar , Rowther Farjana B. , Brown James E. , Oceandy Delvac , Cartwright Elizabeth J. , Wang Weiguang , Gómez-del Arco Pablo , Martínez-Martínez Sara , Neyses Ludwig , Redondo Juan Miguel , Armesilla Angel Luis 
Published: August 2014

Objective—
Vascular endothelial growth factor (VEGF) has been identified as a crucial regulator of physiological and pathological angiogenesis. Among the intracellular signaling pathways triggered by VEGF, activation of the calcineurin/nuclear factor of activated T cells (NFAT) signaling axis has emerged as a critical mediator of angiogenic processes. We and others previously reported a novel role for the plasma membrane calcium ATPase (PMCA) as an endogenous inhibitor of the calcineurin/NFAT pathway, via interaction with calcineurin, in cardiomyocytes and breast cancer cells. However, the functional significance of the PMCA/calcineurin interaction in endothelial pathophysiology has not been addressed thus far.

Approach and Results—

Using in vitro and in vivo assays, we here demonstrate that the interaction between PMCA4 and calcineurin in VEGF-stimulated endothelial cells leads to downregulation of the calcineurin/NFAT pathway and to a significant reduction in the subsequent expression of the NFAT-dependent, VEGF-activated, proangiogenic genes
RCAN1.4
and
Cox-2
. PMCA4-dependent inhibition of calcineurin signaling translates into a reduction in endothelial cell motility and blood vessel formation that ultimately impairs in vivo angiogenesis by VEGF.

Conclusions—
Given the importance of the calcineurin/NFAT pathway in the regulation of pathological angiogenesis, targeted modulation of PMCA4 functionality might open novel therapeutic avenues to promote or attenuate new vessel formation in diseases that occur with angiogenesis.
More Favorable Response to Cardiac Resynchronization Therapy in Women Than in Men
Authors: Cheng Yun-Jiu , Zhang Jing , Li Wei-Jie , Lin Xiao-Xiong , Zeng Wu-Tao , Tang Kai , Tang An-li , He Jian-Gui , Xu Qing , Mei Mei-Yi , Zheng Dong-Dan , Dong Yu-Gang , Ma Hong , Wu Su-Hua 
Published: August 2014

Background—
Data on sex difference in response to cardiac resynchronization therapy (CRT) remain controversial. We conducted a meta-analysis to summarize all published studies to determine whether sex-based differences in response to CRT exist.

Methods and Results—

We performed a literature search using MEDLINE (source PubMed; January 1966 to March 2014) and EMBASE (January 1980 to March 2014) with no restrictions. Pooled effect estimates were obtained by using random-effects meta-analysis. Seventy-two studies involving 33 434 patients were identified. Overall, female patients had better outcomes from CRT compared with male patients, with a significant 33% reduction in the risk of death from any cause (hazard ratio, 0.67; 95% confidence interval, 0.61–0.74;
P
<0.001), 20% reduction in death or hospitalization for heart failure (hazard ratio, 0.80; 95% confidence interval, 0.71–0.90;
P
<0.001), 41% reduction in cardiac death (hazard ratio, 0.59; 95% confidence interval, 0.42–0.84;
P
<0.001), and 41% reduction in ventricular arrhythmias or sudden cardiac death (hazard ratio, 0.59; 95% confidence interval, 0.49–0.70;
P
<0.001). These more favorable responses to CRT in women were consistently associated with greater echocardiographic evidence of reverse cardiac remodeling in women than in men.

Conclusions—
Women obtained greater reductions in the risk of death from any cause, cardiac cause, death or hospitalization for heart failure, and ventricular arrhythmias or sudden cardiac death with CRT therapy compared with men, with consistently greater echocardiographic evidence of reverse cardiac remodeling in women than in men. Further studies are needed to investigate the exact reasons for these results and determine whether indications for CRT in women should be different from men.
Central Sympathetic Inhibition to Reduce Postablation Atrial Fibrillation Recurrences in Hypertensive Patients
Authors: Giannopoulos Georgios , Kossyvakis Charalampos , Efremidis Michael , Katsivas Apostolos , Panagopoulou Vasiliki , Doudoumis Konstantinos , Raisakis Konstantinos , Letsas Konstantinos , Rentoukas Ilias , Pyrgakis Vlasios , Manolis Antonis S. , Tousoulis Dimitrios , Stefanadis Christodoulos , Deftereos Spyridon 
Published: August 2014

Background—
The autonomic system is an important determinant of atrial arrhythmogenesis. Current evidence indicates that a combined sympathovagal drive is most commonly responsible for eliciting atrial fibrillation (AF) episodes. The purpose of this study was to test whether moxonidine, a centrally acting sympathoinhibitory agent, can lead to a reduction in postablation AF recurrence.

Methods and Results—

This was a prospective, double-blinded, randomized study of 291 hypertensive patients with symptomatic paroxysmal AF who were scheduled to undergo pulmonary vein isolation. Patients were randomly assigned to receive either moxonidine (0.2–0.4 mg daily) or placebo, along with standard antihypertensive treatment. No significant differences in blood pressure levels were observed between the 2 groups. In the primary outcome analysis, mean recurrence-free survival was 467 days (95% CI, 445–489 days) in the moxonidine group as compared with 409 days (95% CI, 381–437 days) in control subjects (log rank test,
P
=0.006). The calculated 12-month recurrence rate estimates were 36.9% in the control group and 20.0% in the moxonidine group (
P
=0.007). Moxonidine treatment was associated with lower recurrence risk after adjustment for age, body mass index, number of AF episodes in the previous year, and left atrial diameter (adjusted hazard ratio, 0.35 [95% CI, 0.22–0.55];
P
<0.001).

Conclusions—
Treatment with moxonidine is associated with less AF recurrences after ablation treatment for drug-refractory AF in patients with hypertension. The observed effect does not appear to depend on the antihypertensive action of this agent.

Clinical Trial Registration—

URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT01791699.